Murine models to evaluate novel and conventional therapeutic strategies for cancer

James E Talmadge, Rakesh K Singh, Isaiah J. Fidler, Avraham Raz

Research output: Contribution to journalReview article

290 Citations (Scopus)

Abstract

Animal models, by definition, are an approximation of reality, and their use in developing anti-cancer drugs is controversial. Positive retrospective clinical correlations have been identified with several animal models, in addition to limitations and a need for improvement. Model inadequacies include experimental designs that do not incorporate biological concepts, drug pharmacology, or toxicity. Ascites models have been found to identify drugs active against rapidly dividing tumors; however, neither ascitic nor transplantable subcutaneous tumors are predictive of activity for solid tumors. In contrast, primary human tumor xenografts have identified responsive tumor histiotypes if relevant pharmacodynamic and toxicological parameters were considered. Murine toxicology studies are also fundamental because they identify safe starting doses for phase I protocols. We recommend that future studies incorporate orthotopic and spontaneous metastasis models (syngeneic and xenogenic) because they incorporate mlcroenvironmental interactions, in addition to confirmatory autochthonous models and/or genetically engineered models, for molecular therapeutics. Collectively, murine models are critical in drug development, but require a rational and hierarchical approach beginning with toxicology and pharmacology studies, progressing to human primary tumors to identify therapeutic targets and models of metastatic disease from resected orthotopic, primary tumors to compare drugs using rigorous, clinically relevant outcome parameters.

Original languageEnglish (US)
Pages (from-to)793-804
Number of pages12
JournalAmerican Journal of Pathology
Volume170
Issue number3
DOIs
StatePublished - Mar 2007

Fingerprint

Neoplasms
Toxicology
Pharmaceutical Preparations
Therapeutics
Animal Models
Pharmacology
Molecular Models
Ascites
Heterografts
Research Design
Neoplasm Metastasis

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Murine models to evaluate novel and conventional therapeutic strategies for cancer. / Talmadge, James E; Singh, Rakesh K; Fidler, Isaiah J.; Raz, Avraham.

In: American Journal of Pathology, Vol. 170, No. 3, 03.2007, p. 793-804.

Research output: Contribution to journalReview article

@article{39c1743d79744c5495a3129c2c0fa4cc,
title = "Murine models to evaluate novel and conventional therapeutic strategies for cancer",
abstract = "Animal models, by definition, are an approximation of reality, and their use in developing anti-cancer drugs is controversial. Positive retrospective clinical correlations have been identified with several animal models, in addition to limitations and a need for improvement. Model inadequacies include experimental designs that do not incorporate biological concepts, drug pharmacology, or toxicity. Ascites models have been found to identify drugs active against rapidly dividing tumors; however, neither ascitic nor transplantable subcutaneous tumors are predictive of activity for solid tumors. In contrast, primary human tumor xenografts have identified responsive tumor histiotypes if relevant pharmacodynamic and toxicological parameters were considered. Murine toxicology studies are also fundamental because they identify safe starting doses for phase I protocols. We recommend that future studies incorporate orthotopic and spontaneous metastasis models (syngeneic and xenogenic) because they incorporate mlcroenvironmental interactions, in addition to confirmatory autochthonous models and/or genetically engineered models, for molecular therapeutics. Collectively, murine models are critical in drug development, but require a rational and hierarchical approach beginning with toxicology and pharmacology studies, progressing to human primary tumors to identify therapeutic targets and models of metastatic disease from resected orthotopic, primary tumors to compare drugs using rigorous, clinically relevant outcome parameters.",
author = "Talmadge, {James E} and Singh, {Rakesh K} and Fidler, {Isaiah J.} and Avraham Raz",
year = "2007",
month = "3",
doi = "10.2353/ajpath.2007.060929",
language = "English (US)",
volume = "170",
pages = "793--804",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Murine models to evaluate novel and conventional therapeutic strategies for cancer

AU - Talmadge, James E

AU - Singh, Rakesh K

AU - Fidler, Isaiah J.

AU - Raz, Avraham

PY - 2007/3

Y1 - 2007/3

N2 - Animal models, by definition, are an approximation of reality, and their use in developing anti-cancer drugs is controversial. Positive retrospective clinical correlations have been identified with several animal models, in addition to limitations and a need for improvement. Model inadequacies include experimental designs that do not incorporate biological concepts, drug pharmacology, or toxicity. Ascites models have been found to identify drugs active against rapidly dividing tumors; however, neither ascitic nor transplantable subcutaneous tumors are predictive of activity for solid tumors. In contrast, primary human tumor xenografts have identified responsive tumor histiotypes if relevant pharmacodynamic and toxicological parameters were considered. Murine toxicology studies are also fundamental because they identify safe starting doses for phase I protocols. We recommend that future studies incorporate orthotopic and spontaneous metastasis models (syngeneic and xenogenic) because they incorporate mlcroenvironmental interactions, in addition to confirmatory autochthonous models and/or genetically engineered models, for molecular therapeutics. Collectively, murine models are critical in drug development, but require a rational and hierarchical approach beginning with toxicology and pharmacology studies, progressing to human primary tumors to identify therapeutic targets and models of metastatic disease from resected orthotopic, primary tumors to compare drugs using rigorous, clinically relevant outcome parameters.

AB - Animal models, by definition, are an approximation of reality, and their use in developing anti-cancer drugs is controversial. Positive retrospective clinical correlations have been identified with several animal models, in addition to limitations and a need for improvement. Model inadequacies include experimental designs that do not incorporate biological concepts, drug pharmacology, or toxicity. Ascites models have been found to identify drugs active against rapidly dividing tumors; however, neither ascitic nor transplantable subcutaneous tumors are predictive of activity for solid tumors. In contrast, primary human tumor xenografts have identified responsive tumor histiotypes if relevant pharmacodynamic and toxicological parameters were considered. Murine toxicology studies are also fundamental because they identify safe starting doses for phase I protocols. We recommend that future studies incorporate orthotopic and spontaneous metastasis models (syngeneic and xenogenic) because they incorporate mlcroenvironmental interactions, in addition to confirmatory autochthonous models and/or genetically engineered models, for molecular therapeutics. Collectively, murine models are critical in drug development, but require a rational and hierarchical approach beginning with toxicology and pharmacology studies, progressing to human primary tumors to identify therapeutic targets and models of metastatic disease from resected orthotopic, primary tumors to compare drugs using rigorous, clinically relevant outcome parameters.

UR - http://www.scopus.com/inward/record.url?scp=34247876272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34247876272&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2007.060929

DO - 10.2353/ajpath.2007.060929

M3 - Review article

C2 - 17322365

AN - SCOPUS:34247876272

VL - 170

SP - 793

EP - 804

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 3

ER -